- ZS Pharma has filed to raise $86.25M in an IPO on Nasdaq, where it intends to trade under the symbol ZSPH.
- The biotech develops ZS-9, a treatment for hyperkalemia, which is a life-threatening condition in which high blood-potassium levels increase the risk of muscle dysfunction.
- ZS-9 met its primary and secondary efficacy endpoints in one Phase III trial and is now being tested in another late-stage study. ZS Pharma also plans to start a long-term safety study this quarter.
- ZS Pharma initially filed confidentially for its listing on April 4. (S-9)
- ETF: IPO
ZS Pharma eyes $86M+ IPO
Recommended For You
More Trending News
About IPO ETF
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
IPO | - | - |
Renaissance IPO ETF |